“Nothing to do with geopolitics”: WuXi Biologics CEO bullish in face of Biosecure At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling effect on clients. Fiona Barry, January 16, 2025 https://www.pharmaceutical-technology.com/...sh-in-face-of-biosecure/ -
Efforts revived to stem flow of US funding for China R&D Feb. 10, 2025 By Mari Serebrov "The Biosecure Act may have died with the 118th U.S. Congress, but efforts to stop U.S. government funding of R&D in China are alive and well. Rep. Claudia Tenney, R-N.Y., introduced the Stop Funding our Adversaries Act in the House Feb. 7 to prohibit direct and indirect federal funding of research in China or entities owned by China." https://www.bioworld.com/articles/...ding-for-china-r-and-d?v=preview -
07.02.2025 - U.S. likely to re-enact BIOSECURE Act this year to limit Chinese biotech firms - If BIOSECURE Act is passed, Korean CDMO companies could benefit - Chinese companies may look to establish corporations to bypass BIOSECURE Acts in the U.S. https://www.thebionews.net/news/articleView.html?idxno=12601 |